DDInter624 DDInter1700
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency .
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somatrem
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somatrem
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somatrem
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Efavirenz (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Efavirenz (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem